Technology
Health
Biotechnology

Magenta Therapeutics

$13.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-0.23%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell MGTA and other stocks, options, ETFs, and crypto commission-free!

About MGTA

Magenta Therapeutics, Inc. Common Stock, also called Magenta Therapeutics, is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. Read More It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.

Employees
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
447.65M
Price-Earnings Ratio
Dividend Yield
Average Volume
120.60K
High Today
$13.63
Low Today
$13.08
Open Price
$13.46
Volume
29.11K
52 Week High
$21.00
52 Week Low
$5.31

Collections

Technology
Health
Biotechnology
Medical
Therapy
2018 IPO
US
North America

MGTA Earnings

-$0.67
-$0.59
-$0.52
-$0.44
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.53 per share
Actual
Expected Aug 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.